For the first time in its 15 year history the judges of the GlaxoSmithKline IMPACT Awards could not choose one overall winner for the awards so instead awarded two prizes.

The FINANCIAL -- Pfizer Inc announced that the Phase 3 INTORSECT study, evaluating TORISEL in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT therapy, did not meet the primary endpoint of prolonging progression free survival when compared to sorafenib.

The FINANCIAL -- Results from the pivotal Phase III GLOW2 study demonstrated that once-daily 50 mcg NVA237 was superior to placebo in improving lung function, symptom relief and quality of life, and reducing exacerbations over a one-year period.

The FINANCIAL -- GlaxoSmithKline plc commented on Human Genome Sciences Board of Directors' decision to recommend against GSK’s tender offer to acquire all of the outstanding shares of HGS for US$13.00 per share in cash.

The FINANCIAL -- Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER  extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy.